Biotechnology

Enanta Pharma

Enanta Pharma released FY2026 Semi-Annual earnings on May 11 After-Market EST, actual revenue USD 35.77 M, actual EPS USD -0.87

Enanta Pharma released FY2026 Q2 earnings on May 11 After-Market EST, actual revenue USD 17.16 M (forecast USD 17.09 M), actual EPS USD -0.4507 (forecast USD -0.4873)

Enanta Pharma to Release FY2026 Q2 Earnings on May 11 After-Market EST, Forecast Revenue USD 17.09 M, EPS USD -0.4873

Enanta Pharma released FY2026 Q1 earnings on February 9 After-Market EST, actual revenue USD 18.62 M (forecast USD 15.31 M), actual EPS USD -0.42 (forecast USD -0.8765)

Enanta Pharma to Release FY2026 Q1 Earnings on February 9 After-Market EST, Forecast Revenue USD 15.31 M, EPS USD -0.8765

Enanta Pharma released FY2025 Q4 earnings on November 17 After-Market (EST), actual revenue USD 15.13 M (forecast USD 15.97 M), actual EPS USD -0.8746 (forecast USD -1.014)

Enanta Pharma released FY2025 Annual Earnings on November 17 After-Market (EST), actual revenue USD 65.32 M (forecast USD 66.15 M), actual EPS USD -3.838 (forecast USD -3.7725)

Enanta Pharma to release FY2025 Q4 earnings on November 17 After-Market EST, forecast revenue USD 15.97 M, EPS USD -1.014

Enanta to Present New Data on RSV Drug Candidates at IDWeek

Enanta Pharmaceuticals Reports Positive Clinical Trial Results for RSV Research Drugs

Enanta Pharmaceuticals Completes $74.75 Million Increased Offering of Common Stock

Enanta's RSV Treatment Zelicapavir Fails to Meet Primary Endpoint in Phase II Clinical Trial

Enanta Pharmaceuticals Announces Positive Clinical Trial Results for RSV Drug Zelicapavir

Enanta Pharma released FY2025 Q3 earnings on August 11 After-Market (EST), actual revenue USD 18.31 M (forecast USD 15.63 M), actual EPS USD -0.8539 (forecast USD -0.885)

Enanta Pharma released FY2025 9 Months Earnings on August 11 After-Market EST, with actual revenue of USD 50.2 M and EPS of USD -2.9638

Enanta Pharma to Release FY2025 Q3 Earnings on August 11 After-Market EST, Forecast Revenue USD 15.63 M, EPS USD -0.885

Enanta's MAVYRET® Drug Receives FDA Approval

JPMorgan Maintains Enanta Pharma Rating and Raises Target Price

Enanta to Present Zelicapavir Phase 2 Study Data at ESPID

Enanta Pharmaceuticals Q2 2025 Revenue Falls to $14.9 Million

Amesite

Meiwu Tech

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Generation Income Properties

MetaVia

NextNRG

Co-Diagnostics

Phoenix Asia

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

ENTA

ARKG

SBIO

Enanta Pharmaceuticals Inc. (ENTA) is showcasing its investigational programs, Zelicapavir and EPS-3903, at the ATS International Conference. Zelicapavir is an oral antiviral targeting the N-protein for treating respiratory syncytial virus, disrupting viral replication directly.

rttnews

iShares Biotechnology ETF

iShares US Pharma

VanEck Biotech ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

VG Health

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Enanta Pharma's RSV Bet And Immunology Ambitions

LABU

Enanta Pharmaceuticals Inc reported Q3 2026 revenue of $17.16M, a 15% increase from $14.93M in the previous year. The net loss narrowed to $13.09M from $22.64M, with diluted EPS improving to $(0.45) from $(1.06). Royalty revenue rose due to higher MAVYRET/MAVIRET sales. The RSV program showed positive Phase 2b results, and the immunology pipeline advanced with EDP-978 entering Phase 1. Cash and marketable securities stand at $227M, supporting development through fiscal 2029.

TradingView

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

ENANTA PHARMACEUTICALS INC 3Q 2026: Revenue $17.16M, EPS $(0.45) — 10-Q Summary

Enanta Pharma shares are trading lower. The company reported Q2 financial results.

benzinga_article

Earnings Watch

Enanta Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 17.16 M

Enanta Pharmaceuticals reported its fiscal second quarter results for the period ending March 31, 2026, with total revenue of $17.2 million, up from $14.9 million year-over-year. The company initiated dosing in a Phase 1 trial for EDP-978 and is on track to file an IND for EPS-3903. Enanta's net loss was $13.1 million, improving from a loss of $22.6 million in the same quarter last year. The company has $227 million in cash and marketable securities, ensuring operational funding into fiscal 2029.

StockTitan

Abbvie

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 | ENTA Stock News

ENTA (Enanta Pharmaceuticals, Inc.) is set to announce its Q2'26 results on May 11, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q2'26, revenue estimate is 17.03 million USD with EPS (earnings per share) anticipated at (0.49) USD. Learn more details at .Revenue & EPS values are provided in USDQ2'25Q3'25Q4'25Q1'26Q2'26Revenue Reported14.93 M18.31 M15.12 M18.61 M—Revenue Estimate15.95 M15.54 M15.98 M15.90 M17.03 MRevenue Surprise-6.44%+17.86%-5.32%+17.04%EPS Reported(1.06)(0.85)(0.87)(0.42) EPS Estimate(1.15)(0.90)(1.02)(0.77)(0.49) EPS Surprise+7.56%+5.56%+14.83%+45.29%DisclaimerSelect reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.

Factset Research

ENTA Q2'26 Earnings: revenue estimate is 17.03M USD